[Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease].

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 22678673
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sustained Effects of Once-Daily Memantine Treatment on Cognition and Functional Communication Skills in Patients with Moderate to Severe Alzheimer's Disease: Results of a 16-Week Open-Label Trial

  2011cited by this paper
• Web‐based application to project the burden of Alzheimer's disease

  2010cited by this paper
• Safety and tolerability of once‐daily versus twice‐daily memantine: a randomised, double‐blind study in moderate to severe Alzheimer's disease

  2007cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine)

  1999cited by this paper
• Dementia of the Alzheimer's Type: Changes in Hippocampal L‐[3H]Glutamate Binding

  1987cited by this paper

• Memantine for dementia.

  2019cites this paper